scispace - formally typeset
A

Aliasgar Esmail

Researcher at University of Cape Town

Publications -  64
Citations -  3584

Aliasgar Esmail is an academic researcher from University of Cape Town. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 16, co-authored 48 publications receiving 2059 citations. Previous affiliations of Aliasgar Esmail include South African Medical Research Council & University of London.

Papers
More filters
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

TL;DR: Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.
Journal ArticleDOI

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Nafees Ahmad, +107 more
- 08 Sep 2018 - 
TL;DR: Treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis, and the need for trials to ascertain the optimal combination and duration of these drugs is emphasised.
Journal ArticleDOI

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

Sergey Borisov, +64 more
TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.